Meeting
2011 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB) and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).
Authors
M. Khasraw
Andrew Love Cancer Center, Barwon Health, Geelong, Australia
M. Khasraw , S. A. McCowatt , Z. Kerestes , M. E. Buyse , M. Back , H. Wheeler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01124240
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS133^)
Abstract #
TPS133^
Poster Bd #
40C
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
First Author: Mustafa Khasraw
Poster
2011 ASCO Annual Meeting
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
First Author: V. Verschaeve
Poster
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
First Author: Louis B. Nabors
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi